You are here
Angiochem's technology and products have been well reported in scientific literature and at scientific meetings. Access those articles, posters, and presentations via the links below.
You will need Adobe Acrobat Reader to view these files. A free download is available here >
Demeule M et al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Drappazt et al. Phase I Study of GRN1005 in Recurrent Malignant Glioma
Kurzrock, R. et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics, 12/2/2011.
Bertrand, Y, et.al, Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1, British Journal of Cancer (2011) 105, 1697 – 1707
Demeule M, et al. Involvement of the low-density lipoprotein receptorrelated protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem 2008 10.1111/j.1471-4159.2008.05492.x
Demeule M, et al. Identification and Design of Peptides as a New Drug Delivery System for the Brain, JPET 324:1064-1072, 2008.
Turcotte S, et al. Roles of the Multidrug Resistance Transporter PGlycoprotein. From: Blood Brain Barriers - From ontogeny to artificial interfaces, Dermeitzel R, Spray DS, Nedergaard M, eds. 2006.
Demeule M, et al. Brain Endothelial Cells as Pharmacological Targets in Brain Tumors. Mol Neurobiol 30:157-183, 2004.
Demeule M, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 38:339-348, 2002.
Regina A, et al. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer and Metastasis Reviews 20:13-25, 2001.
Regina A, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008, 1-13.
Thomas FC. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. Pharm Res 2009 26(11): 2486-94
Che C, et al. New Angiopep-Modified Doxorubicin (ANG1007) and Etoposide (ANG1009) Chemotherapeutics With Increased Brain Penetration. J Med Chem, 2010, 53 (7), 2814-2824.
Angiopep-2-conjugated liposomes encapsulating c-secretase inhibitor for targeting glioblastoma stem cells
Synthesis of a ‘‘clickable’’ Angiopep-conjugated p-coumaric acid for brain-targeted delivery
Angiopep-2-Mediated Delivery of Human Manganese Superoxide Dismutase in Brain Endothelial Cells and its Protective Effect Against Oxidative Stress
Fluorescent Carbonaceous Nanodots for Noninvasive Glioma Imaging after Angiopep?2 Decoration
Angiopep-Conjugated Electro-Responsive Hydrogel Nanoparticles: Therapeutic Potential for Epilepsy
A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein
Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma
Two-Order Targeted Brain Tumor Imaging By Using An Optical/ Paramagnetic Nanoprobe across the Blood Brain Barrier
Retro-Inverso Isomer of Angiopep-2: A Stable D?Peptide Ligand Inspires Brain-Targeted Drug Delivery
Angiopep?2 and Activatable Cell-Penetrating Peptide Dual- Functionalized Nanoparticles for Systemic Glioma-Targeting Delivery
Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating
Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas
Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles
Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome
Angiopep-conjugated poly(ethylene glycol)-co-poly(e-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma
Jones AR, Shusta EV. Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation. Pharm Res. 2007 September; 24(9): 1759-1.
Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology & Therapeutics 104 (2004) 29-45.
Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Advanced Drug Delivery Reviews 36 (1999) 179-194.
Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease 37 (2010) 48–57.
Deeken JF, Loscher W. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. Clin Cancer Res 2007;13(6) 1663-1674.
Posters and Presentations
ANG1005, A Novel Brain-Penetrant TaxaneDerivative, for the Treatment of Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer
AACR congress 2014
San Antonio Breast Cancer Symposium 2013
AACR-NCI-EORTC Congress 2013
TIDES Meeting 2013
AACR Annual Meeting April 2013
Society of Neuro-Oncology (SNO) Annual Meeting November 2012
Neuroscience 2012, October 13-17, 2010, New Orleans, LA, USA
AACR/NCI/EORTC Annual Meeting, November 15, 2011, SF, CA
Neurosciences 2010, November 13-17, 2010, San Diego, CA, USA.
ASCO annual meeting 2010, Chicago, IL, June 4-8, 2010.
EORTC-NCI-AACR Annual Meeting 2009, Boston, MA, November 15-19, 2009
Society for Neuroscience Annual Meeting, Chicago, IL, USA, 17/21-Oct-2009
American Association for Cancer Research (AACR) 100th annual meeting, Denver, Colorado, USA, 18/22-Apr-2009
International Brain Barriers/Neuroscience Meeting, Gleneden Beach, Oregon, USA, 19/21-Mar-2009.
SOT 48th Annual Meeting, Baltimore, USA, 15/19 Mar-2009 (for SOT posters)
Society for Neuro-Oncology Annual Meeting, Las Vegas, Nevada, USA, 21/22-Nov-2008
Neuroscience 2008, Washington DC, USA, 18-Nov-2008